Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca

Bristol Myers Squibb surged after a Financial Times report said it held merger talks with AstraZeneca, potentially creating one of the largest pharma deals ever. BMY jumped 7.5% premarket to $70.20, while AstraZeneca ADRs fell 5.8% to $159.73, reflecting a clear market split over the rumored tie-up. The article notes the companies have discussed a combination in recent months, but neither side commented. UBS analyst Matthew Weston questioned the strategic logic, warning that mega-deals can slow drug development and hurt R&D productivity despite Big Pharma’s ongoing M&A activity in 2026. The report highlights valuation context: AstraZeneca at $264 billion and Bristol Myers at $133 billion. Overall, the news is bullish for BMY on takeover speculation, but bearish for AZN due to merger uncertainty and concern over deal execution.